Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas a phase 2 clinical trial

JAMA Oncology

Volumn 4, Issue 1, 2018, Pages 93-97

  Toulmonde, Maud ^a   Penel, Nicolas ^b   Adam, Julien ^c,d   Chevreau, Christine ^c   Blay, Jean Yves ^e   Le Cesne, Axel ^f   Bompas, Emmanuelle ^g   Piperno Neumann, Sophie ^h   Cousin, Sophie ^a   Grellety, Thomas ^a   Ryckewaert, Thomas ^b   Bessede, Alban ⁱ   Ghiringhelli, François ^j   Pulido, Marina ^a,k   Italiano, Antoine ^a  

^a INSTITUT BERGONIÉ   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c Department of Pathology ^*  (France)

^d Universite Paris Sud   (France)

^e CENTRE LÉON BÉRARD   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UMR INSERM U892 CNRS 6299   (France)

^h INSTITUT CURIE   (France)

ⁱ Immusmol   (France)

^j INSERM   (France)

^k Centre of Clinical Investigation Clinical Epidemiology   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; INDOLEAMINE 2,3 DIOXYGENASE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER INHIBITION; CELL INFILTRATION; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOCOMPETENT CELL; LEIOMYOSARCOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SOFT TISSUE SARCOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BONE TUMOR; CELL MOTION; CLINICAL TRIAL; ENZYME ACTIVATION; GASTROINTESTINAL TUMOR; IMMUNOLOGY; METABOLISM; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SARCOMA; SOFT TISSUE TUMOR; YOUNG ADULT;

ADMINISTRATION, METRONOMIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; CELL MOVEMENT; CYCLOPHOSPHAMIDE; ENZYME ACTIVATION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MACROPHAGES; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SARCOMA; SOFT TISSUE NEOPLASMS; YOUNG ADULT;

EID: 85041578001     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.1617     Document Type: Article

References (17)

1. Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14(3):199-220.
2. Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD-1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870.
3. D'Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357-365.
4. Lussier DM, O'Neill L, Nieves LM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother. 2015;38(3):96-106.
5. Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer. 2015;3:36. doi:10.1186/s40425-015-0078-9
6. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-648.
7. Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther. 2011;19(9):1737-1746.
8. Berinstein NL, Oza AM, Odunsi K, et al. Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study. J Clin Oncol. 2013;31:3030.
9. MkrtichyanM, Najjar YG, Raulfs EC, et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol. 2011;41(10): 2977-2986.
10. Kvistborg P, Philips D, Kelderman S, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254ra128.
11. Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019-1031.
12. Toulmonde M, Adam J, Bessede A, et al. Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity. J Clin Oncol. 2016;34:abstr 11008.
13. Khunger M, Rakshit S, Schalper KA, et al. Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors. J Clin Oncol. 2016; 34:abstr 11603.
14. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147-1154.
15. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478 (7368):197-203.
16. D'Angelo SP, Shoushtari AN, Keohan ML, et al. Combined KIT and CTLA-4 Blockade in Patients with refractory GIST and other advanced sarcomas: A phase Ib study of dasatinib plus ipilimumab [published online December 22, 2016]. Clin Cancer Res. doi:10.1158/1078-0432.CCR-16-2349
17. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057-5069.